Angus Liu

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.

The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech.

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Sanofi has suspended distribution of its two flu vaccines in China out of concern of waning potency. BioNTech's antibody-drug conjugate partner, DualityBio, has filed for a Hong Kong IPO. UCB will offload some Chinese assets for $680 million. And more.

Hutchmed, the original developer of Takeda's Fruzaqla, has decided not to pursue an approval for the VEGFR inhibitor in stomach cancer for now in its home country.

Vaxcyte unveiled what analysts called “stunning” phase 1/2 data for its 31-valent pneumococcal vaccine candidate that, if replicated in a large pivotal study, could pose a serious threat to Pfizer's stalwart Prevnar 20.

Novartis is investing more than $200 million to further bolster its radiotherapy infrastructure with a brand-new facility and the expansion of an existing site.

AstraZeneca has found its employees' practices under the microscope of Chinese law enforcement years after an insurance fraud case.

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. The FDA has converted Filspari's conditional nod in the kidney disease IgA nephropathy (IgAN) into a full approval.

Astellas is closing a gene therapy manufacturing facility in South San Francisco. But, across the country, the company opened a new R&D center in Massachusetts.